Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 12;213(13):2861–2870. doi: 10.1084/jem.20161135

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Breton et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 4. — Flt3L mobilizes human CD172a⁻ and CD172a⁺ pre-cDCs into the blood. (a and b) PBMCs from Flt3L-injected volunteers (n = 3; 25 µg/kg for seven consecutive days) were analyzed by flow cytometry before (day 0) and after Flt3L treatment (day 12) to assess the expansion of CD1c⁺ and CD141⁺ cDC subsets as well as CD172a⁻, CD172a^int, and CD172a⁺ pre-cDC subsets in blood. Representative flow cytometry dot plots show CD1c⁺ cDCs (blue) and CD141⁺ cDCs (red; a) as well as CD172a⁻ (red), CD172a^int (green), and CD172a⁺ (blue; b) pre-cDC subsets (gating strategy in Fig. 1, a and c). Gate frequencies from parent population are shown. SSC, side scatter. (c) Representative histogram shows CD117 and HLA-DR expression on CD1c⁺ cDCs, CD141⁺ cDCs, CD172a⁻ pre-cDCs, and CD172a⁺ pre-cDCs in one of the Flt3L-treated volunteers.